Upstream Bio, Inc. Common Stock (UPB)
PHARMACEUTICAL PREPARATIONS
Upstream Bio, Inc. Common Stock (UPB) is listed on Nasdaq, where it has traded since October 11, 2024.
- Listed On
- Nasdaq
- Listed Since
- October 11, 2024
- Employees
- 75
- Market Cap
- $177M
About Upstream Bio, Inc. Common Stock
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases. Verekitug has advanced into three separate world-wide, placebo-controlled, randomized Phase 2 clinical trials, two completed in chronic rhinosinusitis with nasal polyps (CRSwNP) and severe asthma, and one ongoing in chronic obstructive pulmonary disease (COPD).
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 143 institutions reported holding UPB, with 50.6 million shares worth $350.1 million in aggregate. The largest reported holder was FMR, with 8.2 million shares worth $56.5 million. Of the 5 largest holders listed below, 1 opened a new position in UPB, 3 added shares and 1 held its position unchanged during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| FMR | 8,162,897 | $56M | Added 0.76% |
| Orbimed Advisors | 5,693,589 | $39M | Unchanged |
| Norges Bank | 3,768,619 | $26M | New position |
| BlackRock | 3,753,358 | $26M | Added 11.35% |
| Vanguard | 2,868,896 | $20M | Added 0.6% |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is UPB?
Upstream Bio, Inc. Common Stock (UPB) is listed on Nasdaq, where it has traded since October 11, 2024.
Who are the largest institutional holders of UPB?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of UPB were FMR, Orbimed Advisors and Norges Bank.
How many institutions own UPB?
143 institutions reported a position in UPB for the quarter ended June 30, 2026, worth $350.1 million in total.
Did institutions buy or sell UPB last quarter?
Of the 5 largest reported holders, 1 opened a new position in UPB, 3 added shares and 1 held its position unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for UPB.
Every reported institutional holder, plus insider and congressional trades in UPB, on SentiSense.